2011 - TID Conference


EMERGING TOPICS IN TRANSPLANT ID

3.2 - Hepatitis E and Organ Transplant: Everything you need to Know

Presenter: Nassim, Kamar, Toulouse , France
Authors: Nassim Kamar, Toulouse, France


Hepatitis E and Organ Transplant: Everything you need to Know
Nassim Kamar, Toulouse, France
Hepatitis E virus (HEV) infection is an emerging disease in developed countries. Locally acquired HEV genotype-3-infection is thought to be a porcine zoonosis. Until recently, it has been thought to be responsible for acute hepatitis that does not evolve to chronic hepatitis. However, over the last three years, a number of cases of chronic hepatitis caused by HEV genotype 3 have been reported in the immunosuppressed, i.e., solid-organ-transplant (SOT) recipients, and hematological, and HIV patients. Chronic HEV infection can cause rapidly progressive cirrhosis, necessitating liver transplantation. Nearly, 60% of solid-organ-transplant patients infected by HEV develop chronic hepatitis. The use of tacrolimus rather than cyclosporin A, and a low platelet count at HEV diagnosis have been identified as independent predictive factors associated with chronic HEV infection. A decrease of dose and trough levels of immunosuppressive therapy targeting T-cells (i.e., cyclosporin A and tacrolimus) led to HEV clearance in one-third of chronically infected SOT patients. Furthermore, it has been recently shown that pegylated-interferon ╬▒ or ribavirin alone can successfully treat HEV infection, producing a sustained virological response. Finally, HEV-induced neurological symptoms have been reported and HEV RNA has been detected in the cerebrospinal fluid. Hence, HEV infection should be looked for systematically in organ-transplant patients with unexplained hepatitis.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi